NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

CureVac NV (XETRA: 5CV)

 
5CV Technical Analysis
5
As on 9th Jun 2023 5CV STOCK Price closed @ 9.27 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 13.72 & Strong Sell for SHORT-TERM with Stoploss of 17.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

5CVSTOCK Price

Open 9.71 Change Price %
High 9.83 1 Day -0.48 -4.92
Low 9.23 1 Week 0.35 3.92
Close 9.27 1 Month 2.63 39.61
Volume 127454 1 Year -20.83 -69.20
52 Week High 31.23 | 52 Week Low 5.45
 
XETRA Germany Most Active Stocks
LHAR 2.05 -20.23%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BBVA 5.00 -2.72%
BVBA 0.02 -60.00%
SNH 0.16 6.67%
SNH 0.16 6.67%
SNH 0.16 6.67%
AT1 1.15 5.50%
AT1 1.15 5.50%
 
XETRA Germany Top Gainers Stocks
ASKN 0.73 73.81%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
DIS 6.30 26.00%
 
XETRA Germany Top Losers Stocks
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
F03 0.56 -99.14%
BVBA 0.02 -60.00%
SD1 0.13 -51.85%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
MGNK 0.01 -50.00%
CNW 0.24 -29.41%
 
 
5CV
Daily Charts
5CV
Intraday Charts
Whats New @
Bazaartrend
5CV
Free Analysis
 
5CV Important Levels Intraday
RESISTANCE10.43
RESISTANCE10.06
RESISTANCE9.83
RESISTANCE9.60
SUPPORT8.94
SUPPORT8.71
SUPPORT8.48
SUPPORT8.11
 
5CV Forecast April 2024
4th UP Forecast22.66
3rd UP Forecast18.37
2nd UP Forecast15.71
1st UP Forecast13.06
1st DOWN Forecast5.48
2nd DOWN Forecast2.83
3rd DOWN Forecast0.17
4th DOWN Forecast-4.12
 
5CV Weekly Forecast
4th UP Forecast23.82
3rd UP Forecast19.15
2nd UP Forecast16.27
1st UP Forecast13.38
1st DOWN Forecast5.16
2nd DOWN Forecast2.27
3rd DOWN Forecast-0.61
4th DOWN Forecast-5.28
 
5CV Forecast2024
4th UP Forecast57.5
3rd UP Forecast42.03
2nd UP Forecast32.47
1st UP Forecast22.91
1st DOWN Forecast-4.37
2nd DOWN Forecast-13.93
3rd DOWN Forecast-23.49
4th DOWN Forecast-38.96
 
 
5CV Other Details
Segment EQ
Market Capital 6198986240.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
5CV Address
5CV
 
5CV Latest News
 
Your Comments and Response on CureVac NV
 
5CV Business Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service